Medicinal Properties of Tinospora Cordifolia (Guduchi)
Tinospora cordifolia is one of the most important medicinal plant commonly known as Giloy belonging to menispermaceae family is a deciduous climbing shrub described known for its immense application in the treatment of various diseases such as jaundice, fever, diabetes, and skin diseases etc.The chemical constituents of this shrub belong to different classes such as alkaloid, lactones, steroids, phenolics, aliphatic compound, glycosides and polyscharide compounds having medical importance.
The chemical constituents and diverse pharmacological importance of Tinospora cordifolia
Tinospora cordifolia is a popular medicinal plant which is used in several traditional medicines to cure various diseases. The common names are Amrita and Guduchi and belong to the family of Menispermaceae. It is considered an essential herbal plant of Indian system of medicine (ISM) and has been used in the treatment of fever, urinary problem, dysentery, skin diseases leprosy, diabetes, and many more diseases. The plant reported containing chemical compound including Alkaloids, Terpenoids, Lignans, Steroids and others that establish the phytochemistry and pharmacological activity of Tinospora cordifolia. The present review highlights the pharmacological importance viz antioxidant activity, antimicrobial activity, antibacterial activity, antifungal activity, anti-diabetic activity, antistress activity, hypolipidaemic effect, hepatic disorder, anticancer anti HIV potential, antiosteoporotic effects, antitoxic effects, wound healing, anticomplementary activity, and immunomodulating activity, systemic infection and Parkinson's disease.
Evaluation of the antineoplastic activity of guduchi (Tinospora cordifolia) in Ehrlich ascites carcinoma bearing mice.
The anticancer activity of dichloromethane extract of guduchi [Tinospora cordifolia (Willd.) Miers ex Hook. F. & Thoms. Family: Menispermaceae (TCE)] in the mice transplanted with Ehrlich ascites carcinoma (EAC) was investigated. The EAC mice receiving 25, 30, 40, 50 and 100 mg/kg, TCE showed a dose dependent elevation in tumor-free survival and a highest number of survivors were observed at 50 mg/kg TCE, which was considered as an optimum dose for its neoplastic action. The average survival time (AST) and median survival time (MST) for this dose were approximately 56 and 55 d, respectively when compared with 19 d of non-drug treated controls. Administration of 50 mg/kg TCE resulted in 100% long-term survivors (up to 90 d). An attempt was also made to evaluate the effectiveness of TCE in the various stages of tumor development, where 50 mg/kg TCE was administered intraperitoneally after 1, 3, 6, 9, 12 or 15 d of tumor inoculation and these days have been arbitrarily designated as stage I, II, III, IV or V, respectively for reasons of clarity. The greatest anticancer activity was recorded for stage I, II and III where number of long term survivors (LTS) was approximately 33, 25 and 17%, respectively. However, treatment of mice at stage IV and V did not increase LTS, despite an increase in AST and MST. The EAC mice receiving 50 mg/kg TCE showed a time dependent depletion in the glutathione (GSH) activity up to 12 h post-treatment and marginal elevation thereafter. This depletion in GSH was accompanied by a drastic elevation in lipid peroxidation (LPx) and a maximum elevation in LPx was observed at 6 h that declined gradually thereafter. TCE exerted cytotoxic effect on tumor cells by reducing the GSH concentration and increase in LPx simultaneously.